Aprepitant + Palonosetron + Dexamethasone
Phase 2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Nausea and Vomiting
Conditions
Chemotherapy-Induced Nausea and Vomiting, Lung Cancer
Trial Timeline
Dec 1, 2015 → May 1, 2016
NCT ID
NCT02445872About Aprepitant + Palonosetron + Dexamethasone
Aprepitant + Palonosetron + Dexamethasone is a phase 2 stage product being developed by Merck for Chemotherapy-Induced Nausea and Vomiting. The current trial status is unknown. This product is registered under clinical trial identifier NCT02445872. Target conditions include Chemotherapy-Induced Nausea and Vomiting, Lung Cancer.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-Induced Nausea and Vomiting were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02445872 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Chemotherapy-Induced Nausea and Vomiting